HH-003 + NRTIs

HH-003 + NRTIs is a combination therapy under investigation for the treatment of chronic hepatitis B virus (HBV) infection. HH-003 is a monoclonal antibody targeting the hepatitis B virus, and it is being studied in combination with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), which are standard antiviral agents used to suppress HBV replication. The primary indication for this combination is HBeAg-negative chronic hepatitis B in patients already receiving NRTI therapy, such as entecavir or tenofovir disoproxil fumarate. The mechanism of action involves direct neutralization of HBV by the monoclonal antibody (HH-003), while NRTIs inhibit viral DNA synthesis by acting as chain terminators during reverse transcription[1].